American Journal of Respiratory and Critical Care Medicine

Papers
(The H4-Index of American Journal of Respiratory and Critical Care Medicine is 73. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline1209
Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease480
A Single-Cell Atlas of the Human Healthy Airways335
Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis263
Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis256
Tissue-Specific Immunopathology in Fatal COVID-19250
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes235
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary235
Symptoms of Anxiety, Depression, and Peritraumatic Dissociation in Critical Care Clinicians Managing Patients with COVID-19. A Cross-Sectional Study195
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial195
Ventilatory Variables and Mechanical Power in Patients with Acute Respiratory Distress Syndrome194
Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision192
Air Pollution, Genetic Factors, and the Risk of Lung Cancer: A Prospective Study in the UK Biobank188
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele174
A New Global Definition of Acute Respiratory Distress Syndrome172
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study170
Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease158
Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome157
Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids155
Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline154
An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal153
Sleep Apnea–Specific Hypoxic Burden, Symptom Subtypes, and Risk of Cardiovascular Events and All-Cause Mortality151
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study150
From GOLD 0 to Pre-COPD143
Inflammatory Endotype–associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis137
Secretory Cells Dominate Airway CFTR Expression and Function in Human Airway Superficial Epithelia136
Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU132
New Physical, Mental, and Cognitive Problems 1 Year after ICU Admission: A Prospective Multicenter Study126
Effect of Lowering Vt on Mortality in Acute Respiratory Distress Syndrome Varies with Respiratory System Elastance125
Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial120
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical 120
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension117
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis117
Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia115
Necroptosis Signaling Promotes Inflammation, Airway Remodeling, and Emphysema in Chronic Obstructive Pulmonary Disease114
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled T113
Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement110
The Epidemiological Importance of Subclinical Tuberculosis. A Critical Reappraisal110
Single-Cell Reconstruction of Human Basal Cell Diversity in Normal and Idiopathic Pulmonary Fibrosis Lungs108
Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case–Control Study107
The Sleep Apnea–Specific Pulse-Rate Response Predicts Cardiovascular Morbidity and Mortality106
Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study105
Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles104
Using Bayesian Methods to Augment the Interpretation of Critical Care Trials. An Overview of Theory and Example Reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial101
Lung Ultrasound to Monitor Extremely Preterm Infants and Predict Bronchopulmonary Dysplasia. A Multicenter Longitudinal Cohort Study99
Mitigating Inequities and Saving Lives with ICU Triage during the COVID-19 Pandemic99
Trends in Intensive Care for Patients with COVID-19 in England, Wales, and Northern Ireland98
Air Pollution as a Risk Factor for Incident Chronic Obstructive Pulmonary Disease and Asthma. A 15-Year Population-based Cohort Study97
High Prevalence of Pulmonary Sequelae at 3 Months after Hospital Discharge in Mechanically Ventilated Survivors of COVID-1996
Sleep Apnea and COVID-19 Mortality and Hospitalization96
A Race-neutral Approach to the Interpretation of Lung Function Measurements93
Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement93
Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances93
Multinight Prevalence, Variability, and Diagnostic Misclassification of Obstructive Sleep Apnea93
ACE2 Elevation in Severe COVID-1992
Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers90
Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline90
Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial88
Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes86
Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline86
Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward86
Compliance Phenotypes in Early Acute Respiratory Distress Syndrome before the COVID-19 Pandemic85
Chronic Hypersensitivity Pneumonitis, an Interstitial Lung Disease with Distinct Molecular Signatures84
YTHDF1 Regulates Pulmonary Hypertension through Translational Control of MAGED181
Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists80
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial80
Episodic Aspiration with Oral Commensals Induces a MyD88-dependent, Pulmonary T-Helper Cell Type 17 Response that Mitigates Susceptibility to Streptococcus pneumoniae78
Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial77
Latent Tuberculosis: Two Centuries of Confusion76
Asthma in Adult Patients with COVID-19. Prevalence and Risk of Severe Disease75
Reconsidering the Utility of Race-Specific Lung Function Prediction Equations74
Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review74
Equitably Allocating Resources during Crises: Racial Differences in Mortality Prediction Models74
Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial73
0.092611789703369